


Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Claim 1 (currently amended). A composition for the treatment of dry eye and other disorders requiring the wetting of the eye comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of one or more compounds of the following formula I:



wherein:

R<sup>1</sup> is CO<sub>2</sub>R, CONR<sup>2</sup>R<sup>3</sup>, CH<sub>2</sub>OR<sup>4</sup>, CH<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, CH<sub>2</sub>N<sub>3</sub>, CH<sub>2</sub>Hal, CH<sub>2</sub>NO<sub>2</sub>, CH<sub>2</sub>SR<sup>20</sup>, COSR<sup>21</sup>, or 2,3,4,5-tetrazol-1-yl, wherein:

R is H or CO<sub>2</sub>R forms a pharmaceutically acceptable salt or a pharmaceutically acceptable ester;

NR<sup>2</sup>R<sup>3</sup> and NR<sup>5</sup>R<sup>6</sup> are the same or different and comprise a free or functionally modified amino group, with the proviso that at most only one of R<sup>2</sup> and R<sup>3</sup> is OH or alkoxy and at most only one of R<sup>5</sup> and R<sup>6</sup> is OH or alkoxy;

OR<sup>4</sup> comprises a free or functionally modified hydroxy group;

Hal is F, Cl, Br, or I;

SR<sup>20</sup> comprises a free or functionally modified thiol group; and

R<sup>21</sup> is H or COSR<sup>21</sup> forms a pharmaceutically acceptable salt or a pharmaceutically acceptable thioester;


A, B and D are the same or different and are C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>2</sub>-C<sub>5</sub> alkenyl, C<sub>2</sub>-C<sub>5</sub> alkynyl, or a C<sub>3</sub>-C<sub>5</sub> allenyl group;

C is cyclopropanecyclopropyl;

X is (CH<sub>2</sub>)<sub>m</sub> or (CH<sub>2</sub>)<sub>m</sub>O, wherein m is 1-6; and

Y is a phenyl ring optionally substituted with alkyl, halo, trihalomethyl, acyl, or a free or functionally modified hydroxy, amino, or thiol group; or

X-Y is (CH<sub>2</sub>)<sub>p</sub>Y<sup>1</sup>; wherein p is 0-6; and



wherein:

W is CH<sub>2</sub>, O, S(O)<sub>q</sub>, NR<sup>8</sup>, CH<sub>2</sub>CH<sub>2</sub>, CH=CH, CH<sub>2</sub>O, CH<sub>2</sub>S(O)<sub>q</sub>, CH=N, or CH<sub>2</sub>NR<sup>8</sup>; wherein q is 0-2, and R<sup>8</sup> is H, alkyl, or acyl;

Z is H, alkyl, acyl, halo, trihalomethyl, or a free or functionally modified amino, thiol, or hydroxy group; and

==== is a single or double bond;


or X-Y is cyclohexyl or *n*-C<sub>5</sub>H<sub>11</sub>.

Claim 2 (cancelled).

Claim 3 (cancelled).

Claim 4 (original). The composition of Claim 1, wherein the composition is a topical ophthalmic formulation.

Claim 5 (currently amended). A method for the treatment of dry eye and other disorders requiring the wetting of the eye which comprises administering to a mammal a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of one or more compounds of the following formula I:



wherein:

R<sup>1</sup> is CO<sub>2</sub>R, CONR<sup>2</sup>R<sup>3</sup>, CH<sub>2</sub>OR<sup>4</sup>, CH<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, CH<sub>2</sub>N<sub>3</sub>, CH<sub>2</sub>Hal, CH<sub>2</sub>NO<sub>2</sub>, CH<sub>2</sub>SR<sup>20</sup>, COSR<sup>21</sup>, or 2,3,4,5-tetrazol-1-yl, wherein:

R is H or CO<sub>2</sub>R forms a pharmaceutically acceptable salt or a pharmaceutically acceptable ester;

NR<sup>2</sup>R<sup>3</sup> and NR<sup>5</sup>R<sup>6</sup> are the same or different and comprise a free or functionally modified amino group, with the proviso that at most only one of R<sup>2</sup> and R<sup>3</sup> is OH or alkoxy and at most only one of R<sup>5</sup> and R<sup>6</sup> is OH or alkoxy;

OR<sup>4</sup> comprises a free or functionally modified hydroxy group;

Hal is F, Cl, Br, or I;

SR<sup>20</sup> comprises a free or functionally modified thiol group; and

R<sup>21</sup> is H or COSR<sup>21</sup> forms a pharmaceutically acceptable salt or a pharmaceutically acceptable thioester;


A, B and D are the same or different and are C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>2</sub>-C<sub>5</sub> alkenyl, C<sub>2</sub>-C<sub>5</sub> alkynyl, or a C<sub>3</sub>-C<sub>5</sub> allenyl group;

C is ~~an oxirane~~ cyclopropyl;

X is (CH<sub>2</sub>)<sub>m</sub> or (CH<sub>2</sub>)<sub>m</sub>O, wherein m is 1-6; and

Y is a phenyl ring optionally substituted with alkyl, halo, trihalomethyl, acyl, or a free or functionally modified hydroxy, amino, or thiol group; or

X-Y is (CH<sub>2</sub>)<sub>p</sub>Y<sup>1</sup>; wherein p is 0-6; and



wherein:

W is CH<sub>2</sub>, O, S(O)<sub>q</sub>, NR<sup>8</sup>, CH<sub>2</sub>CH<sub>2</sub>, CH=CH, CH<sub>2</sub>O, CH<sub>2</sub>S(O)<sub>q</sub>, CH=N, or CH<sub>2</sub>NR<sup>8</sup>; wherein q is 0-2, and R<sup>8</sup> is H, alkyl, or acyl;

Z is H, alkyl, acyl, halo, trihalomethyl, or a free or functionally modified amino, thiol, or hydroxy group; and

---- is a single or double bond;

or X-Y is cyclohexyl or *n*-C<sub>5</sub>H<sub>11</sub>.


Claim 6 (cancelled).

Claim 7 (cancelled).

Claim 8 (original). The method of Claim 5, wherein the composition is a topical ophthalmic formulation.

Claim 9 (original). The method of Claim 5 wherein the dry eye and other disorders requiring the wetting of the eye is symptoms of dry eye associated with refractive surgery.

Claim 10 (currently amended). A compound of the following formula I:



wherein:

$R^1$  is  $CO_2R$ ,  $CONR^2R^3$ ,  $CH_2OR^4$ ,  $CH_2NR^5R^6$ ,  $CH_2N_3$ ,  $CH_2Hal$ ,  $CH_2NO_2$ ,  $CH_2SR^{20}$ ,  $COSR^{21}$ , or 2,3,4,5-tetrazol-1-yl, wherein:

$R$  is  $H$  or  $CO_2R$  forms a pharmaceutically acceptable salt or a pharmaceutically acceptable ester;

$NR^2R^3$  and  $NR^5R^6$  are the same or different and comprise a free or functionally modified amino group, with the proviso that at most only one of  $R^2$  and  $R^3$  is  $OH$  or alkoxy and at most only one of  $R^5$  and  $R^6$  is  $OH$  or alkoxy;

$OR^4$  comprises a free or functionally modified hydroxy group;

$Hal$  is  $F$ ,  $Cl$ ,  $Br$ , or  $I$ ;

$SR^{20}$  comprises a free or functionally modified thiol group; and

$R^{21}$  is  $H$  or  $COSR^{21}$  forms a pharmaceutically acceptable salt or a pharmaceutically acceptable thioester;


A, B and D are the same or different and are C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>2</sub>-C<sub>5</sub> alkenyl, C<sub>2</sub>-C<sub>5</sub> alkynyl, or a C<sub>3</sub>-C<sub>5</sub> allenyl group;

C is ~~an oxiranecyclopropyl~~;

X is (CH<sub>2</sub>)<sub>m</sub> or (CH<sub>2</sub>)<sub>m</sub>O, wherein m is 1-6; and

Y is a phenyl ring optionally substituted with alkyl, halo, trihalomethyl, acyl, or a free or functionally modified hydroxy, amino, or thiol group; or

X-Y is (CH<sub>2</sub>)<sub>p</sub>Y<sup>1</sup>; wherein p is 0-6; and



wherein:

W is CH<sub>2</sub>, O, S(O)<sub>q</sub>, NR<sup>8</sup>, CH<sub>2</sub>CH<sub>2</sub>, CH=CH, CH<sub>2</sub>O, CH<sub>2</sub>S(O)<sub>q</sub>, CH=N, or CH<sub>2</sub>NR<sup>8</sup>; wherein q is 0-2, and R<sup>8</sup> is H, alkyl, or acyl;

Z is H, alkyl, acyl, halo, trihalomethyl, or a free or functionally modified amino, thiol, or hydroxy group; and

---- is a single or double bond;

or X-Y is cyclohexyl or *n*-C<sub>5</sub>H<sub>11</sub>.

Claim 11 (cancelled).

Claim 12 (cancelled).